^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Leiomyosarcoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

    Published date:
    05/28/2021
    Excerpt:
    Seventy-five patients met inclusion criteria. Of these, 25 received a treatment based on identified alterations; 1 had a complete response (CR), 4 had partial responses (PR), and 4 experienced disease stabilization (SD). We identified two patients with MET amplified sarcoma that responded to treatment with crizotinib. One other patient with a diagnosis of leiomyosarcoma was found to have an unusually high total mutational burden (TMB) and experienced complete pathologic response to dual checkpoint blockade...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

    Published date:
    05/19/2021
    Excerpt:
    One other patient with a diagnosis of leiomyosarcoma was found to have an unusually high total mutational burden (TMB) and experienced complete pathologic response to dual checkpoint blockade....Ipilimumab + Nivolumab – CR, ongoing 1.5+ yrs...
    DOI:
    10.1200/JCO.2021.39.15_suppl.11538